Abstract
Objective: The opioid epidemic is a major public health concern. However, little is known about opioid use among rheumatoid arthritis (RA) patients. We undertook this study to examine trends in chronic opioid use in RA patients in 2002–2015 and to identify clinical predictors. Methods: RA patients were identified from the Corrona registry. Opioid use was ascertained from surveys obtained at clinical visits as often as every 3 months. Chronic opioid use was defined as any opioid use reported during ≥2 consecutive study visits. Annual prevalence of chronic opioid use was calculated using data from 33,739 RA patients with information on opioid use from ≥2 visits. Among the 26,288 individuals who were not taking opioids at baseline, Cox proportional hazards models identified associations between patient characteristics and incident chronic opioid use. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated. Results: Chronic opioid use increased from 7.4% in 2002 to 16.9% in 2015. Severe pain (HR 2.53 [95% CI 2.19–2.92]) and antidepressant use (HR 1.79 [95% CI 1.64–1.92]) were associated with an increased risk of chronic opioid use. High disease activity (HR 1.55 [95% CI 1.30–1.84]) and a high level of disability (HR 1.45 [95% CI 1.27–1.65]) were also associated with chronic opioid use, whereas Asian ethnicity (HR 0.49 [95% CI 0.36–0.68]) was associated with a decreased risk of chronic opioid use. Conclusion: Among RA patients, chronic opioid use doubled from 2002 to 2015. Pain and antidepressant use were the strongest predictors of chronic opioid use. To curb the rise in chronic opioid use, strategies for stringent control of RA disease activity and management of pain and depression should be research priorities.
Original language | English (US) |
---|---|
Pages (from-to) | 670-677 |
Number of pages | 8 |
Journal | Arthritis and Rheumatology |
Volume | 71 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Funding
Dr. Lee has served on the advisory board of Eli Lilly, has received research support from Pfizer, and owns stock or stock options in Express Scripts. Dr. Kremer has received consulting fees and/or honoraria from AbbVie, Gilead, Eli Lilly, and Pfizer (less than $10,000 each), has received research support from AbbVie, Eli Lilly, Novartis, and Pfizer, and owns stock or stock options in Corrona. Dr. Greenberg owns stock or stock options in Corrona. Dr. Solomon has received research support from AbbVie, Amgen, Janssen, Genentech, and Pfizer. No other disclosures relevant to this article were reported.
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology